Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Portage Biotech is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Portage Biotech has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Portage Biotech. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Portage Biotech's earnings available for a low price, and how does
this compare to other companies in the same industry?
Unable to compare the PB ratio to the industry average as no data exists.
Examine Portage Biotech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Portage Biotech's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Portage Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Portage Biotech's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Portage Biotech's earnings growth to the Canada market average as no estimate data is available.
Unable to compare Portage Biotech's revenue growth to the Canada market average as no estimate data is available.
Unable to determine if Portage Biotech is high growth as no earnings estimate data is available.
Unable to determine if Portage Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Portage Biotech has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data. You can see them here.
Show me the analysis anyway
No data on Portage Biotech's last earnings update.
The past performance of a company can be measured by how much
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Below we compare
Portage Biotech's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it
has maintained that growth in the year.
Insufficient past earnings data to establish if Portage Biotech's year on year earnings growth rate was positive over the past 5 years.
Unable to compare Portage Biotech's 1-year growth to the 5-year average as past earnings data has not been reported.
Unable to compare Portage Biotech's 1-year growth to the North America Biotechs industry average as past earnings data has not been reported.
Earnings and Revenue History
over the past 5 years is shown below, any years where they have experienced a
loss will show up in red.
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
Unable to establish if Portage Biotech has efficiently used shareholders’ funds last year as no Return on Equity data is available.
Unable to establish if Portage Biotech has efficiently used its assets last year compared to the North America Biotechs industry average (Return on Assets) as past financial data has not been reported.
Unable to establish if Portage Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
Portage Biotech's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
In this section we usually analyse Portage Biotech's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Portage Biotech has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information. You can see them here.
Show me the analysis anyway
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Portage Biotech's finances.
The net worth of a company is the difference between its assets and liabilities.
Unable to compare short term assets to short term liabilities as Portage Biotech has not reported sufficient balance sheet data.
Unable to establish if Portage Biotech's long term commitments exceed its cash and other short term assets as Portage Biotech has not reported sufficient balance sheet data.
This treemap shows a more detailed breakdown of
Portage Biotech's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Unable to establish if Portage Biotech has a high level of physical assets or inventory without balance sheet data.
Portage Biotech has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
All data from Portage Biotech Company Filings, last reported .
Portage Biotech has no debt.
Portage Biotech has not taken on any debt in the past 5 years.
Portage Biotech has no debt, it does not need to be covered by operating cash flow.
Portage Biotech has no debt, therefore coverage of interest payments is not a concern.
Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. Portage Biotech's cash and debt levels may be found in its annual reports archived here.
Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Portage Biotech's financial data was last updated here.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Ian B. Walters, M.D., M.B.A., has been Chief Executive Officer of Portage Biotech Inc. since May 6, 2019 and serves as its Director. Dr. Walters Founded SalvaRx (LON: SALV) in 2015. Dr. Walters Founded iOx Therapeutics and serves as its and Chief Executive Officer. He serves as Chairman of The Board of Stimunity SAS. He is the Chairman of the Board of RIFT Biotherapeutics Inc. and has been its Director since March 2017. He is Entrepreneur in Residence at Medqiventures. He is an experienced life science entrepreneur who has helped found and launched several life science companies. He also serves as a part time Chief Medical Officer for Intensity Therapeutics. He was an Independent Director at Portage Biotech Inc. since August 1, 2016. Dr. Walters has led drug development teams in several therapeutic areas and contributed to bringing 4 blockbuster products to market, including OpdivoÂ®, YervoyÂ®, and VelcadeÂ®. Dr. Walters worked at Bristol-Myers Squibb (BMS), where he managed physicians overseeing the international development of more than 8 oncology compounds as well as biomarker and companion diagnostic work. He also was a core member of BMS's Strategic Transactions Group evaluating and executing licensing agreements, mergers and acquisitions and clinical collaborations. Before entering the private sector, Dr. Walters was a lead investigator at the Rockefeller University and initiated cutting edge immunology research to understand the mechanism of action of several compounds. He has over 20 year career, he demonstrated both leadership and expertise in drug development, including the advancement of multiple cancer compounds from research stages through approval. His previous positions include drug development and business roles at PDL BioPharma, Inc., Millenium Pharmaceuticals, Inc., and Sorrento Therapeutics, Inc. Dr. Walters received his MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of the University of Pennsylvania.
Insufficient data for Ian to compare compensation growth.
Insufficient data for Ian to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
CEO & Director
CFO & Director
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Portage Biotech board of directors is about average.
Board of Directors
CEO & Director
CFO & Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Portage Biotech, Inc., a pharmaceutical company, identifies, finances, and develops early-to-mid stage products. It owns 52% interest in Biohaven Pharmaceuticals, a company that is developing glutamatergic therapies for affective disorders and other indications; and owns Portage Pharmaceuticals Limited, which is developing a cell penetrating peptide platform; and also has a minority investment in Sentien Biotechnology. Portage Biotech, Inc. is based in Toronto, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.